Zobrazeno 91 - 100
of 176
pro vyhledávání: '"Andrew Belch"'
Autor:
John Catalano, Lugui Qiu, Annette Ervin-Haynes, Michele Cavo, Philippe Moreau, Donna E. Reece, S. Vincent Rajkumar, Nizar J. Bahlis, Antonio Pinto, Thierry Facon, Heinz Ludwig, Guang Chen, Rik Schots, Andrew Belch, Cyrille Hulin, Richard Leblanc, Meletios A. Dimopoulos, Jennifer Marek
Publikováno v:
ResearcherID
8524 Background: MPT is considered a standard treatment (Tx) option in many countries for SCT-ineligible pts with NDMM. The FIRST trial showed that continuous Rd improved progression-free survival ...
Autor:
Randy D. Gascoyne, Michael Crump, Jean Powers, Laurie H. Sehn, Richard Klasa, Elizabeth Eisenhauer, Andrew Belch, John J. Wright, C.T. Kouroukis
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 18(1)
Background: We evaluated the activity and toxic effects of bortezomib in patients with mantle cell lymphoma. Patients and methods: Thirty patients, including 29 eligible patients, were enrolled; 13 had received no prior chemotherapy. The dose of bort
Autor:
Johannes Drach, Helgi van de Velde, Angela Dascalescu, Olga Samoilova, Lixia Pei, Zvenyslava Masliak, Brendan Rooney, Andrew Belch, Charles M. Farber, Udomsak Bunworasate, André Bosly, Jan Novák, Tadeusz Robak, Huiqiang Huang, Jan Maciej Zaucha, Kateryna Vilchevskaya, Franco Cavalli
Publikováno v:
Blood. 124:3064-3064
Background: The LYM-3002 study compared the efficacy and safety of frontline VR-CAP (n=243) vs R-CHOP (n=244) in newly diagnosed MCL pts who were ineligible or not considered for autologous stem cell transplantation. VR-CAP substitutes bortezomib for
Autor:
Cyrille Hulin, Kevin W. Song, Annette Ervin-Haynes, Fritz Offner, Guang Chen, Philippe Rodon, Ulrich Dührsen, Andrew Belch, Shaker R. Dakhil, Hannah Hunter, Isabelle Azais, Maria Teresa Petrucci, Chaim Shustik, Jin Lu, Laurent Garderet, Thierry Facon, Vanessa Houck, Margaret Macro, Richard Eek, Brigitte Pegourie
Publikováno v:
Blood. 124:81-81
Background: In the pivotal FIRST trial, a randomized, international, multicenter phase 3 study, continuous Rd compared with melphalan-prednisone-thalidomide (MPT) improved progression-free survival (PFS) which was the primary endpoint (HR = 0.72; P <
Autor:
Laith Dabbagh, Andrew Belch, Carol E. Cass, Raymond Lai, Laura Q M Chow, John R. Mackey, James D. Young
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 18(4)
The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. Deficiency in hENT1 confers resistance to toxicity of th
Autor:
Michael J. Mant, Jeff K. Vallance, Lee W. Jones, Kerry S. Courneya, Aliya B. Ladha, Douglas A. Stewart, Andrew Belch, Tony Reiman
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 12(11)
The goal of this study was to examine the association between exercise and quality of life (QOL) in multiple myeloma cancer survivors.Using a retrospective design, 156 multiple myeloma cancer survivors were mailed a questionnaire that assessed self-r
Autor:
George P. Browman, B. Osterwalder, Richard Klasa, A. Muldal, Elizabeth Eisenhauer, Andrew Belch
Publikováno v:
Annals of Oncology. 6:721-723
Background : Several studies have shown that interferon α as a single agent produces responses in multiple myeloma patients, and may prolong remission duration. In vitro studies of interleukin-2 (rHu-IL-2) in multiple myeloma models indicate that rH
Autor:
Michael, Hedenus, Magnus, Adriansson, Jesus, San Miguel, Mark H H, Kramer, Martin R, Schipperus, Eeva, Juvonen, Kerry, Taylor, Andrew, Belch, Albert, Altés, Giovanni, Martinelli, David, Watson, James, Matcham, Gregory, Rossi, Timothy J, Littlewood
Publikováno v:
British journal of haematology. 122(3)
This phase 3, randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients (n = 344) with lymphoma or myeloma received darb
Autor:
Andrew Belch, Tony Reiman, Linda M. Pilarski, Jonathan J Keats, Brian J. Taylor, Michael J. Mant, Loree Larratt, Christopher A. Maxwell
Publikováno v:
Blood. 101(4)
This study analyzed the frequency and clinical significance of t(4;14)(p16;q32) in multiple myeloma (MM) among 208 patients with MM and 52 patients with monoclonal gammopathy of undetermined significance (MGUS); diagnosed between 1994 and 2001. Patie
Autor:
Donna E. Reece, Jonathan Sussman, Judy-Anne W. Chapman, Tony Reiman, Ralph M. Meyer, Martha Q. Lacy, Chaim Shustik, Annette E. Hay, Nizar J. Bahlis, Andrew Belch, Kate Whelan, Jean Roy, A. Keith Stewart, Suzanne Trudel, Darrell White, Michael J. Kovacs, Waleed Sabry, Lois E. Shepherd, Liting Zhu
Publikováno v:
Journal of Clinical Oncology. 32:8591-8591
8591 Background: Primary analysis of the MY.10 trial (Stewart, Blood 2013) demonstrated, with a median f/u of 4.1 yrs, MM patients completing ASCT and randomized to receive 4 yrs of TP experienced ...